In-vitro and in-vivo studies on novel chitosan-g-pluronic f-127 copolymer based nanocarrier of amphotericin b for improved antifungal activity

Journal of Biomaterials and Tissue Engineering

Volumn 4, Issue 3, 2014, Pages 210-216

  Kumar, Vivek ^a   Gupta, Pramod K ^a   Pawar, Vivek K ^a   Verma, Ashwni ^a   Khatik, Renuka ^a   Tripathi, Priyanka ^a   Shukla, Prasant ^a   Yadav, Bholenath ^a   Parmar, Jeetesh ^a   Dixit, Rohit ^a   Mishra, P R ^a   Dwivedi, Anil Kumar ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Fungizone; Micelles; Mycosis; Nanomedicine; Toxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CHITOSAN G PLURONIC F 127 COPOLYMER; COPOLYMER; NANOCARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICAL AGGREGATION CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOLYSIS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MICELLE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PHYSICAL PARAMETERS; SCANNING ELECTRON MICROSCOPY; TOXICITY TESTING; ULTRAVIOLET SPECTROSCOPY; ZETA POTENTIAL;

EID: 84906335210     PISSN: 21579083     EISSN: 21579091     Source Type: Journal    
DOI: 10.1166/jbt.2014.1160     Document Type: Article

References (16)

1. U. Eriksson, B. Seifert, and A. Schaffner, Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial. BMJ 322, 579 (2001).
2. N. Nishiyama and K. Kataoka, Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 112, 630 (2006).
3. S. Q. Liu, Y. W. Tong, and Y. Y. Yang, Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-bpoly(D,L-lactide-co-glycolide) with varying compositions. Biomaterials 26, 5064 (2005).
4. A. V. Kabanov, E. V. Batrakova, and V. Y. Alakhov, Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Rel. 82, 189 (2002).
5. T. Chandy and C. P. Sharma, Chitosan as biomaterial. Biomater. Artif. Org. 18, 1 (1990).
6. J. W. Bae, D. H. Go, and K. D. Park, Thermosensitive chitosan as an injectable carrier for local drug delivery. Macromol. Res. 14, 461 (2006).
7. J. Cha, W. B. Lee, C. R. Park, Y. W. Cho, C. H. Ahn, and I. C. Kwon, Preparation and characterization of cisplatin-incorporated chitosan hydrogels, microparticles, and nanoparticles. Macromol. Res. 14, 573 (2006).
8. J. W. Lee, M. C. Jung, H. D. Park, K. D. Park, and G. H. Ryu, Synthesis and characterization of thermosensitive chitosan copolymer as a novel biomaterial. J. Biomater. Sci. Polym. Ed. 15, 1065 (2004).
9. K. M. Park, J. W. Bae, Y. K. Joung, J. W. Shin, and K. D. Park, Nanoaggregate of thermosensitive chitosan-Pluronic for sustained release of hydrophobic drug. Colloids and Surfaces B: Biointerfaces 63, 1 (2008).
10. G. Gaucher, M. H. Dufresne, V. P. Sant, N. Kang, D. Maysinger, and J. C. Leroux, Block copolymer micelles: Preparation, characterization and application in drug delivery. J. Control. Rel. 109, 169 (2005).
11. S. Y. Kim, I. G. Shin, Y. M. Lee, C. S. Cho, and Y. K. Sung, Methoxy poly(ethylene glycol) and epsilon-caprolactone amphiphilic block copolymeric micelle containing indomethacin. II. Micelle formation and drug release behaviours. J. Control. Rel. 51, 13 (1998).
12. Y. Ali and K. Lehmussaari, Industrial perspective in ocular drug delivery. Adv. Drug. Deliv. Rev. 58, 1258 (2006).
13. A. V. Kabanov, P. Lemieux, and S. Vinogradov, Pluronic block copolymers: Novel functional molecules for gene therapy. Adv. Drug Deliv. Rev. 54, 223 (2002).
14. M. S. Espuelas, P. Legrand, M. A. Campanero, M. Appel, M. Chéron, C. Gamazo, G. Barratt, and J. M. Irache, Polymeric carriers for amphotericin B: In vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J. Antimicrob. Chemother. 52, 419 (2003).
15. M. L Adams, D. R. Andes, and G. S. Kwon, Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-blockpoly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules 4, 750 (2003).
16. C. P. Schröder, E. G. E. de Vries, N. H. Mulder, P. H. B. Willemse, D. T. Sleijfer, G. A. P. Hospers, and W. T. A. van der Graaf, Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. J. Antimicrob. Chemother. 43, 741 (1999).